New liposome chemo shows promise in early cancer trial
NCT ID NCT04047251
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hope the liposome delivery may improve how the drug targets tumors while reducing harm to healthy tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FF-10850 (topotecan liposome injection)
- What this could lead to
- If successful, this could lead to a safer, more effective version of topotecan for hard-to-treat cancers like ovarian, cervical, and Merkel cell carcinoma.
- What could go wrong
- This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may cause side effects or fail to shrink tumors in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02215, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43221, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?